
Novartis AG NVS
€ 128.46
1.47%
Geschäftsbericht 2025
hinzugefügt 14.03.2026
Novartis AG DSO 2011-2026 | NVS
DSO Jährlich Novartis AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 0.045 | 0.0412 | - | 75.3 | 76.4 | 69.8 | 78.3 | 79.5 | 76.1 |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 79.5 | 0.0412 | 56.9 |
DSO anderer Aktien in der Pharmaeinzelhändler
| Name | DSO | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Altimmune
ALT
|
7.85 K | $ 3.45 | 3.29 % | $ 304 M | ||
|
Amgen
AMGN
|
81.2 | $ 351.92 | 1.18 % | $ 189 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
70.9 | $ 19.55 | 0.26 % | $ 914 M | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Ascendis Pharma A/S
ASND
|
132 | $ 218.41 | -1.57 % | $ 5 B | ||
|
Aytu BioScience
AYTU
|
150 | $ 2.61 | - | $ 16.4 M | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | ||
|
Benitec Biopharma
BNTC
|
141 | $ 11.01 | 0.27 % | $ 453 M | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Compugen Ltd.
CGEN
|
60.8 | $ 2.08 | -0.48 % | $ 194 M | ||
|
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Coherus BioSciences
CHRS
|
559 | $ 1.59 | 4.28 % | $ 186 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
9.68 | $ 0.6 | -1.9 % | $ 6.87 M | ||
|
Cellectis S.A.
CLLS
|
94.5 | $ 3.37 | 0.75 % | $ 116 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | ||
|
CorMedix
CRMD
|
130 | $ 6.32 | 1.12 % | $ 455 K | ||
|
Checkpoint Therapeutics
CKPT
|
6.83 | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | ||
|
Denali Therapeutics
DNLI
|
1.89 | $ 20.96 | 3.92 % | $ 3.45 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.26 | 0.35 % | $ 707 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M |